N

Safety Notice 009/22

Issue date 27 July 2022

Distributed to:

Chief Executives

Directors of Clinical Governance

Director, Regulation and Compliance Unit

Action required by:

Chief Executives

Directors of Clinical Governance

We recommend you also inform:

Directors, Managers and Staff of:

- Medicine
- Nursing and Midwifery
- Sleep Laboratories
- Respiratory Departments
- Paediatrics

Biomedical Engineers

Staff caring for home care patients on continuous and non-continuous ventilation

Expert Reference Group Content reviewed by:

HealthShare NSW EnableNSW

Agency Clinical Innovation

Respiratory, Sleep Medicine, Paediatric, Spinal Clinicians

Ministry of Health

Clinical Excellence Commission

Tel: 02 9269 5500

Email:

CEC-

Recalls@health.nsw.gov.au

Internet Website:

http://health.nsw.gov.au/sab

Intranet Website:

http://internal.health.nsw.go v.au/quality/sabs

> Review date July 2023

UPDATE: Philips Sound Abatement Foam on selected sleep and respiratory devices

Situation

What is new in this safety notice?

- A staged remediation/replacement program has been underway since November 2021¹
- In NSW, some affected devices remain unregistered with Philips
- Philips is contacting prescribers to obtain up-to-date settings for their registered patients' devices²
- Philips is contacting all registered patients to confirm device usage (active/inactive), contact and shipping details
- Philips is contacting some registered patients to obtain the current settings for their device via phone, mail amail and SMS
- Some patients have received replacement devices with incorrect settings¹.

Patients continue to be advised not a cease use of affected devices without speaking to their clinician or prescriber who can advise on the benefits of continuing their by with these devices against the risks related to the sound abatement foar.

Background

In July 2021, the Ther peutic Goods Administration (TGA) issued two product defect correction notices (RC-2021-RN-01372-1 and RC-2021-RN-01373-1) for second continuous and non-continuous ventilators (certain CD in Bi-Level PAP and Ventilator Devices). Issues relating to the foar used to lower the sound and vibration emitted by these devices in the contraction.

- The pam may degrade into particles which may enter the devices' air pathy ay and be ingested or inhaled by the user. The foam degradation may be exacerbated by use of unapproved cleaning methods, such as ozone
- The foam may off-gas certain chemicals. Product testing has demonstrated that off-gassing mostly occurs during initial operation and may possibly continue throughout the device's useful life.

To date, the following incidents have been reported:

- The presence of black particles within the airpath circuit (extending from the device outlet, humidifier, tubing, and mask)
- General symptoms such as headache, upper airway, skin and eye irritation, cough, chest pressure, sinus infection and inflammatory responses.

If a patient identifies black particles within the airpath circuit or has general symptoms that are related to their device, they should contact their clinician/prescriber and Philips for further advice/assistance to remediate/replace their device.





Safety Notice 009/22

Assessment

Affected devices are in use within the Australian hospital system and by direct customer purchase via retail pharmacy outlets. These devices include^{1,3}:

No.	Model	Also known as	Remediation/replacement commenced
1	DreamStation CPAP Pro	DreamStation CPAP	November 2021
	DreamStation Auto CPAP		
	System One (50 Series) CPAP		
	System One (50 Series) Auto CPAP		
2	DreamStation BiPAP autoSV	DreamStation ASV	December 2021
	DreamStation BiPAP AVAPS	DreamStation AVAPS	
	DreamStation BiPAP S/T	DreamStation S/T	
	System One BiPAP AVAPS (C-Series)	C Series AVAPS (50 Series)	
		C Series AVAPS (60 Series)	
	System One BiPAP S/T (C-Series)	C Series S/T (60 Series)	
	System One BiPAP autoSV,	SystemOne ASV4 (50 Series)	
	System One BiPAP autoSV Advanced	SystemOne ASV4 (60 Series)	
3	System One (60 Series) CPAP	REMstar Pro CPAP	March 2022
	System One (60 Series) Auto CPAP		
4	Trilogy 100 Ventilator		April 2022
5	BiPAP A40 Ventilator (A-Series)	A-Series BiPAP A40	To be advised
	BiPAP A30 Ventilator (A-Series)	A-Series BiPAP A30	
	OmniLab Advanced Plus		
	DreamStation GO		

To identify a device that has been remediated check if the ULL is included in the device label (sticker). See the below before and after labels and compare with that on the device.



Recommendations

In the course of providing healthcare in NSW, you may be in contact with patients who use an affected Philips Respironics device.

For patients with devices not yet remediated:

- Check if the device has been registered and a patient script has been provided to Philips
- Inspect the airpath circuit for black particles
- Assess the patient for any symptoms related to their device
- Escalate any concerns regarding the patient's need for prioritisation for early rectification to Philips, EnableNSW and/or the treating physician/clinician, as required.





Safety Notice 009/22

Recommendations cont:

Patients with remediated devices:

- Check that the correct patient settings have been applied to their remediated device
- Escalate any concerns regarding incorrect settings to the treating physician/clinician, EnableNSW and/or Philips, as required.

Contact details:

To register a device, provide script details, enquires or for escalation of concerns:

- EnableNSW customers: 1800 362 253, select option 3, or via email enable@health.nsw.gov.au
- Physician/clinician only enquiries: Philips 1800 830 517, select option 2 (Physicians), or via email srcanz.support@Philips.com
- Direct purchase customers: Philips 1800 009 579 or visit the website at www.philips.com/src-update.

Reporting incidents:

Please include in your ims+ notification:

Equipment tab "Manufacturer" field: Philips Respironi

Device Model:
As recorded on the covice and left and left

Device Serial Number:
SN Alpha/numeric om device label

If the device has been remediated, include date of the device, if known.

Required actions for the Local Health District Clerks

- Distribute this Safety Notice to all relevant NSV Health stakeholders
- Ensure there is a process for risk assessment and estallation for patients who are using these devices
- Provide families/carers with information and education on safe management and use of affected Philips respiratory support devices as required
- Report any incidents associate with the devices into ims+ and TGA.

References

- 1. Therapeutic Goods Administra on. 2022 Philips recall action for CPAP, Bi-Level PAP devices and mechanical ventilators [Online]. Available at: https://www.au/alert/philips-recall-action-cpap-bi-level-pap-devices-and-mechanical-ventilators#t1 [Accessed 14 July 2022].
- 2. EnableNSW. 2022. *Philips Respiratory Devices information for prescribers, TGA Product Defect Correction on some Philips respiratory devices* [Online]. Available at: https://www.enable.health.nsw.gov.au/services/hrp/philips-respiratory-devices-information-for-prescribers [Accessed 14 July 2022]
- 3. Philips. 2022. *Philips Sleep and Respiratory Care Devices Australia and New Zealand* [Online]. Available at: https://www.philips.com.au/healthcare/e/sleep/communications/src-update#affected_devices [Accessed 14 July 2022]
- 4. Philips. 2022. URGENT: Medical Device Recall, Philips Respironics CPAP and Bi-Level PAP Devices [Online]. Available at: https://www.usa.philips.com/c-dam/b2bhc/master/landing-pages/src/update/documents/en_US/philips-recall-letter-2021-11-16-a-cpap-a-ventilator-recall-letter-us-revised.pdf [Accessed 14 July 2022].

